LATEST NEWS
May 15, 2023 at 4:01 PM EDT
April 21, 2023 at 7:30 AM EDT
Latest News
Latest News
THE OPHTHALMOLOGY MEDICINES COMPANY
Kodiak Sciences is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases globally
OUR MISSION
Kodiak aims to prevent and treat the leading causes of blindness in the developed world
TRAILBLAZING SCIENCE
OUR CREATIVE AND THOUGHTFUL FOUNDATION
“GO-TO” MEDICINES
OUR CHALLENGE TO THE STATUS QUO
SINGULAR FOCUS IN OPHTHALMOLOGY
OUR 24/7/365
OUR PRODUCT CANDIDATES
We intend to progress our portfolio of three late-stage clinical assets as rapidly as we can into Phase 3 value inflection points.
Tarcocimab Tedromer
High-prevalence retinal
vascular diseases
Diabetic retinopathy
Retinal vein occlusion
Wet AMD
Phase 3
KSI-501
High-prevalence retinal
vascular diseases
Wet AMD
Diabetic macular edema
Phase 3 study initiation targeted mid-2024
KSI-101
Macular edema
associated with inflammation
Phase 2b/3 study initiation targeted 2024
Tarcocimab tedromer
Tarcocimab tedromer
Anti-VEGF biopolymer conjugate
Anti-VEGF biopolymer conjugate
Tarcocimab tedromer is an investigational anti-VEGF therapy designed to address the leading unmet need of durability for patients with high-prevalence retinal vascular diseases.
Built on our Antibody Biopolymer Conjugate (“ABC”) Platform that is precision engineered for long-interval durability, tarcocimab demonstrated what Kodiak believes is strong and consistent durability of approximately 6 months for the majority of patients and favorable safety across the full Phase 3 program. With the go-to-market formulation with a number of improvements,
we believe tarcocimab has the potential to become an important medicine for patients. Learn more
Tarcocimab is our most advanced program. We have important learnings from six pivotal studies across four major retinal diseases and maintain our conviction that tarcocimab could be an important medicine. With tarcocimab’s signature durability and safety record, as demonstrated in multiple studies, we believe tarcocimab could be differentiated in the market as a longest-acting biologic based on its ABC Platform design. Our objective is to finish the clinical development program and enable the marketing application. Learn more
KSI-501
KSI-501
Anti-IL-6 and VEGF trap bispecific antibody biopolymer conjugate
Anti-IL-6 and VEGF trap bispecific antibody biopolymer conjugate
The pathophysiology of retinal vascular and hyperpermeability disorders is multifactorial. In addition to VEGF-mediated fluid and leakage, IL-6 stimulates defective angiogenesis, is implicated in anti-VEGF treatment resistance, and is associated with disease progression in high-prevalence retinal diseases.
KSI-501 is a first-in-class, anti-IL-6, VEGF trap bispecific antibody biopolymer conjugate built on our Antibody Biopolymer Conjugate (“ABC”) platform and is being developed for high-prevalence retinal vascular diseases to address the unmet needs of targeting multiple biologies and extended durability. Learn more
The pathophysiology of retinal vascular and hyperpermeability disorders is multifactorial. In addition to VEGF-mediated fluid and leakage, IL-6 stimulates defective angiogenesis, is implicated in anti-VEGF treatment resistance, and is associated with disease progression in high-prevalence retinal diseases.
KSI-501 is a first-in-class, anti-IL-6, VEGF trap bispecific antibody biopolymer conjugate built on our Antibody Biopolymer Conjugate (“ABC”) platform and is being developed for high-prevalence retinal vascular diseases to address the unmet needs of targeting multiple biologies and extended durability. Learn more
KSI-101
KSI-101
Anti-IL-6 and VEGF trap bispecific protein
Anti-IL-6 and VEGF trap bispecific protein
KSI-101 is a novel bispecific protein targeting IL-6 and VEGF for the treatment of macular edema associated with inflammation.
Currently there are no available intravitreal biologic therapies addressing the spectrum of inflammatory conditions of the retina. We believe that KSI-101 has the potential to meaningfully help patients with retinal fluid and inflammation by being a first-in-class biologic that addresses the underlying mechanisms of disease. Learn more
KSI-101 is a novel bispecific protein targeting IL-6 and VEGF for the treatment of macular edema associated with inflammation.
Currently there are no available intravitreal biologic therapies addressing the spectrum of inflammatory conditions of the retina. We believe that KSI-101 has the potential to meaningfully help patients with retinal fluid and inflammation by being a first-in-class biologic that addresses the underlying mechanisms of disease. Learn more
THE ABC OF OUR SCIENCE
We are bringing new science to the design and development of next generation retinal medicines. Our Antibody Biopolymer Conjugate (ABC) Platform uses a bio-inspired polymer to enable multi-modal, multi-mechanistic treatment of complex ocular and systemic diseases.
Antibody Biopolymer Conjugate
- Designed-in durability
- Designed to target multiple intracellular and extracellular mechanisms simultaneously
- Designed for ocular and systemic diseases
OUR CULTURE AND VALUES
We are actively building a place, our Kodiak Village, where we are inspired, where we feel valued, and where we can grow our personal and professional journeys while advancing our mission. Historically referred to within Kodiak as the 4 C’s, our values are:
CURIOSITY
Staying fresh.
Asking why.
Being naturally inquisitive.
CREATIVITY
A safe place to think outside the box.
A focus on how to solve the problem.
COMPASSION
For ourselves.
For our colleagues.
For our patients.
COURAGE
Saying no when that’s the right answer.
Saying yes when that’s the right answer.
Regardless.
WORKING AT KODIAK
We aspire to global leadership in ophthalmology through internal focus and by aggregating top talent, technologies, discoveries and ideas.
